There is controversy regarding whether to report concentrations of high-sensitivity cardiac troponin T (hs-cTnT) to the limit of blank (LOB) (3 ng/L) or the limit of detection (LOD) (5 ng/L) of the assay in community-based cohorts. We hypothesized that hscTnT concentrations between the LOB and LOD would be associated with poorer cardiovascular outcomes compared to concentrations below the LOB.
hs-cTnT (3-5, 9, 10 ) and hs-cTnI (11) (12) (13) (14) . Three of these studies, including the Cardiovascular Health Study (CHS) (3 ), Atherosclerosis Risk in Communities (ARIC) Study (4 ) , and Dallas Heart Study (DHS) (5 ), reported hs-cTnT values down to the LOB and suggested an increased prevalence of cardiovascular risk factors, increased evidence of structural cardiac abnormalities with cardiac imaging, and a poorer prognosis with hs-cTnT concentrations above the LOB. However, the cutpoints tested in these studies did not focus specifically on the LOB-to-LOD range (3) (4) .99 ng/L) (3) (4) (5) . Therefore, we sought to more definitively determine the significance of hs-cTnT values between the LOB and LOD vs those below the LOB by performing a unique analysis of the cross-sectional associations and long-term prognostic data from these 3 cohorts both individually and combined in a metaanalysis.
Materials and Methods

STUDY ORGANIZATION AND PARTICIPANTS
Three community-based cohort studies were combined for these analyses. These included the CHS, in which hs-cTnT was measured in 4221 community-dwelling adults older than 65 years enrolled from 1989 to 1990 in the main cohort or 1992 to 1993 in an African American supplementary cohort; the ARIC study, which measured hs-cTnT in 9698 individuals between the ages of 54 and 74 years enrolled from 1987 to 1989 who did not have a history of coronary heart disease or stroke; and the DHS, in which hs-cTnT was measured in 3546 individuals between the ages of 30 and 65 years enrolled between the years 2000 and 2002, with intentional oversampling of African Americans. Included for our analysis were participants with baseline hs-cTnT values of Ͻ3 ng/L or between the LOB and LOD (3) (4) .99 ng/L). Excluded from the present analyses were those with prevalent heart failure.
BIOMARKER ANALYSIS
Methods for measurement of hs-cTnT in all 3 cohorts have been previously described (3) (4) (5) . All 3 studies used previously frozen blood samples with serum for CHS and plasma for ARIC and DHS and a similar methodology and reagents for the measurement of the biomarker (Troponin T hs STAT, Elecsys-2010, in CHS/DHS and Cobas e411 in ARIC, Roche Diagnostics, lot numbers 153401 in CHS, 153401/154102 in ARIC, and 153401 in DHS). The hs-cTnT concentration at which the CV was Ͻ10% was 13 ng/L.
CROSS-SECTIONAL ASSOCIATIONS AND LONGITUDINAL
OUTCOMES
Cross-sectional associations with demographics, cardiovascular risk factors, and prevalent cardiovascular disease were analyzed in all 3 cohorts. In addition, cardiac imaging data from DHS, including cardiac MRI (cMRI) information for left ventricular structure and function, and cardiac computed tomography (CT) scan information for coronary calcium was analyzed. All 3 cohorts provided differentiated long-term cardiovascular outcomes for incident heart failure and cardiovascular death. Ascertainment and adjudication of these outcomes is reported in the initial hs-cTnT publication from each cohort. Study-based adjudication panels were used to determine the diagnosis in CHS and DHS, and the ARIC investigators used discharge diagnostic codes (3) (4) (5) 15 ) .
STATISTICAL ANALYSIS
The cross-sectional associations of the 3 cohort populations were compared using an unpaired t-test for normally distributed variables, a Mann-Whitney U-test for the nonnormally distributed continuous variables, and 2 test for the binary variables. For longitudinal outcomes, cumulative incidence rates of heart failure and cardiovascular death in each group were calculated per 100 person-years for each cohort. Unadjusted and age-, sex-, and race (black vs other)-adjusted multivariate analyses were performed within each cohort by using Cox proportional hazard regression models with those with hs-cTnT concentrations below the LOB as the reference group. Additional multivariate modeling using Cox proportional hazard regression models was performed to further adjust for traditional cardiovascular risk factors, including hypertension, diabetes, smoking history, total cholesterol, and HDL cholesterol (HDL-c). Multivariate modeling for each cohort was slightly different, but maintained to be consistent with the optimized models in the original publications (3) (4) (5) .
A fixed-effect metaanalysis was performed using regression coefficients and variance estimates from fully adjusted models from all 3 cohorts for both outcomes.
Cochrane's Q test demonstrated the absence of significant heterogeneity across the 3 studies. Given that each cohort has been so well represented in prior literature, a modified MOOSE (Metaanalysis Of Observational Studies in Epidemiology) protocol was used to report the data (16 ) . SPSS version 21 (IBM SPSS Statistics, IBM Corporation) and Stata version 12.1 (Stata Corporation) were used for the statistical analysis [metaan command (17 ) ].
Results
PARTICIPANT CHARACTERISTICS
The baseline characteristics of the CHS, ARIC, and DHS populations that comprised our study groups are listed in Table 1 . Our analysis included 1427, 3256, and 2589 participants with hs-cTnT below the LOB from CHS, ARIC, and DHS, respectively. There were 579, 2504, and 368 participants with hs-cTn between the LOB and LOD in each study, respectively. Compared with participants with hs-cTnT concentrations below the LOB, those with hs-cTnT between 3 and 4.99 ng/L in each cohort were older, more likely to be male, and had a greater prevalence of traditional cardiovascular risk factors, with the exception of smoking. In addition, poorer renal function and higher N-terminal pro-type B natriuretic peptide (NT-proBNP) concentrations were observed in the group with higher hs-cTnT in both the middle-aged adults from DHS and the older adults in ARIC and CHS (Table 1) .
CROSS-SECTIONAL ASSOCIATION WITH CARDIAC PATHOLOGY
The prevalence of left ventricular structural abnormalities and extent of coronary calcium in the DHS cohort are shown in Table 1 . Participants with hs-cTnT concentrations between the LOB and LOD had higher coronary calcium scores and left ventricular mass, a greater prevalence of left ventricular hypertrophy, and a lower leftventricular ejection fraction compared with participants with hs-cTnT below the LOB.
LONGITUDINAL CARDIOVASCULAR OUTCOMES
The median follow-up periods in CHS were 15.6 years for cardiovascular death and 15.1 years for incident heart failure. In ARIC the corresponding median follow-up periods were 14.3 years and 14.2 years, respectively. For DHS the median follow-up periods were 9.3 years and 9.4 years, respectively. In CHS there were a total of 348 cardiovascular deaths and 462 incident heart failure events in both study groups. In ARIC there were 193 cardiovascular deaths and 428 incident heart failure hospitalizations. In DHS, with a shorter follow-up and younger median age, there were only 33 cardiovascular deaths and 22 cases of incident heart failure. Table 2 shows the associations of hs-cTnT group with incident heart failure, and Table 3 shows associa- Table 2 . Incidence and association of hs-cTnT with heart failure (CHS and DHS) and heart failure hospitalization (ARIC). a Outcomes presented as unadjusted and adjusted HR by the following models: model 1 (demographics) adjusted for age, sex, and race, model 2 (demographics + traditional cardiovascular risk factors) adjusted for model 1 and hypertension, diabetes, smoking status, HDL, and total cholesterol. In the CHS cohort, model 2 is adjusted for model 1 and history of coronary heart disease, smoking status, systolic blood pressure, heart rate, serum glucose, creatinine, albumin concentrations, and left ventricular hypertrophy by electrocardiogram. b ARIC outcome is incident heart failure hospitalization based on International Classification of Diseases (ICD)-9 codes. c Model 2 in CHS consists of adjustments for demographics and health ABC model. tions with cardiovascular death. The incidence rate of heart failure was higher for those with cTnT between the LOB and LOD across all 3 cohorts. In an unadjusted analysis, the risk for heart failure was 33%-128% higher in the group with hs-cTnT between the LOB and LOD compared to the group with hs-cTnT below the LOB across the 3 cohorts, which was significant in the CHS and ARIC cohorts. After adjustments for demographics and risk factors, the increased risk remained significant in only the ARIC cohort. In the metaanalysis combining outcome results across the 3 studies, hs-cTnT concentrations between the LOB and LOD were significantly associated with incident heart failure in the fully adjusted model [hazard ratio (HR), 1.18; 95% CI, 1.02-1.38; Cochrane's Q(2), 2.92, P ϭ 0.2 for test of heterogeneity] (Fig. 1A) . Similarly, the incidence rate of cardiovascular death was higher in those with hs-cTnT between the LOB and LOD compared with those with hs-cTnT below the LOB in all 3 cohorts. In unadjusted analysis, there was a significant 56%-138% increased risk of cardiovascular mortality for participants with hs-cTnT between the LOB and LOD across the 3 cohorts. In the adjusted models, this remained significant in CHS and ARIC, and in the metaanalysis of the 3 studies, participants with hs-cTnT concentrations between the LOB and LOD had a 29% increased risk of cardiovascular death in the fully adjusted model [HR ϭ 1.29, 95% CI, 1.06 -1.57; Cochrane's Q(2) ϭ 0.33, P ϭ 0.849 for test of heterogeneity] (Fig. 1B) .
Discussion
In 3 large community-based cohorts, participants with hs-cTnT concentrations between the LOB and LOD demonstrated a higher-risk cardiovascular phenotype than did participants with concentrations below the LOB, with a greater burden of cardiovascular risk factors and subclinical cardiovascular disease. Furthermore, we show a higher risk of incident heart failure and cardiovascular mortality among individuals with concentrations between the LOB and LOD than in those with concentrations below the LOB. Both cross-sectional findings and outcomes are consistent across 3 demographically diverse cohorts. Point estimates were similar across cohorts, with differences in P values related more to sample size and event rates: CHS participants were at highest risk and DHS at lowest risk, consistent with differences likely reflected by age. The results of the studies are supported by the metaanalysis, which had a large number of overall events and demonstrated significant associations of hscTnT concentrations between the LOB and LOD with both heart failure and cardiovascular mortality.
Given that the populations in our study are community-dwelling adults mostly without acute cardiovascular symptoms it is not unexpected that a relatively large proportion has hs-cTnT concentrations below 5 ng/L. The question of the clinical significance of these hs-cTnT values between the LOB and LOD is a source of ongoing debate (18 ) . Reanalysis of results from these community cohorts provides robust data to support the clinical importance of these very low hs-cTnT concentrations in this range, demonstrating important differences in pathological features and cardiovascular outcomes in individuals with hs-cTnT concentrations between the LOB and LOD vs those below the LOB. These findings have important implications for the ongoing development of hs troponin assays, illustrating that when evaluating general population cohorts, any concentration of cardiac troponin above the LOB is associated with subclinical cardiovascular disease and has adverse prognostic implications. The results of this analysis also emphasize the importance of improving the low-end accuracy of the hs-cTnT assay for prognostication purposes in the general and chronic disease populations.
The strengths of this analysis are the large number of participants and having both cross-sectional findings and long-term outcomes across several demographically het- erogeneous populations. Each study contributed unique aspects to the present analysis. DHS uses high-resolution structural imaging data in the form of cMRI to contribute to cardiovascular phenotyping, and both CHS and ARIC present robust outcome data in terms of incident heart failure and cardiovascular death in the group with very low circulating hs-cTnT concentrations. The crosssectional associations of low concentrations of hs-cTnT (below the LOD) with cardiac structural abnormalities have also been seen in other cohorts (19 ) . Although the mechanism for persistent troponin release into circulation is not fully understood, several theories have been presented. Previous studies of patients with known coronary disease have shown that persistent low concentrations of circulating cTnT are more predictive of heart failure than coronary disease (2 ). Although we did not present the incidence of coronary heart disease in our current analysis, it was not shown to be associated with very low hs-cTnT in the ARIC study cohort (4 ) . This is suggestive of ongoing myocyte injury, which may result from increased myocyte turnover, necrosis, apoptosis, or inflammation, rather than epicardial coronary atherosclerosis (20, 21 ) .
LIMITATIONS
One of the limitations of our study is that the analytical CV (degree of imprecision) is high at this low end of measurement and biological variability will also influence the results (22 ) . Individual values cannot be relied on for specific patients. Therefore, making individual patient decisions using values between the LOB and LOD could be problematic. However, the purpose of this analysis is to evaluate the prognostic implications in cohorts of community-dwelling individuals without acute cardiovascular symptoms. The findings from this study may be influenced and explained by analytical factors related to reporting of the LOB and LOD values by the manufacturer. The actual values for the LOB and LOD would typically equalize in this type of study involving large populations with low values of hs-cTnT. Additionally, there may be overestimation of the LOB in the hs-cTnT assays when using blank samples with matrix properties similar to the native samples for calibration, and as a result, the LOD may be lower than calculated by the CLSI EP17-A method used and reported in the Instructions for Use (IFU) for the assay (8 ) . Finally, the manufacturer of the hs-cTnT may have conservatively reported LOB and LOD values lower than indicated by the IFU. In aggregate the low concentrations of hs-cTnT detected between the LOB and LOD of the assay represent part of the continuum of increased risk associated with progressively higher concentrations of hs-cTnT. Another limitation of our study is that the DHS cohort itself is not powered for outcomes in this range of hs-cTnT given the low risk of the population and thus the small number of events. However, the trend in DHS was similar to CHS and ARIC and the metaanalysis of the cohorts showed significant results. Lastly, this metaanalysis used study-level rather than patient-level data, combining results from risk-factoradjusted models developed specifically for each cohort; differences in risk-factor adjustment across the study may have influenced the estimated overall associations of hs-cTnT concentration with incident heart failure and cardiovascular death. However, to maintain consistency with the results of the primary studies, we maintained the same covariates in the multivariate models (3) (4) (5) .
FUTURE DIRECTIONS
Our study shows an association between very low circulating hs-cTnT concentrations in the blood just above the assay LOD and adverse outcomes. Further longitudinal studies with serial hs-cTnT monitoring are needed to fully define the natural history of such very low concentrations of hs-cTnT that are just above the LOD and to identify potential strategies to mitigate long-term risk. Potential future studies to test the clinical importance of measuring these low concentrations in the general population include evaluating the utility of primary prevention strategies on subsequent adverse cardiovascular outcomes in patients who have these low concentrations of hs-cTnT. The clinical uncertainty caused by inadequate precision of the assay will be clarified only when more precise assay platforms have been developed. Moving forward, improvement of the hs assay to more accurately measure results of cTnT in the 3-4.99 ng/L range will be important for individual decision-making. Until that time confusion may remain as to whether to report values to the LOB or LOD. We would advocate for non-acute coronary syndrome population-based prognosis studies to report values down to the concentration of the LOB for the hs-cTnT assay.
Conclusion
We show using 3 large community-based cohorts that the presence of hs-cTnT concentrations between the LOB and LOD (3-4.99 ng/L) is associated with a higher cardiovascular risk factor burden, more cardiac pathology, and poorer outcomes compared to concentrations below the LOB. For population cohort studies, hs-cTnT concentrations can be reported down to the LOB and individuals with values between the LOB and LOD should be differentiated from those with concentrations below the LOB.
